We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$356M
AUM Growth
+$69.2M
Cap. Flow
+$89M
Cap. Flow %
25.02%
Top 10 Hldgs %
43.39%
Holding
101
New
33
Increased
27
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$23M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.27M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$8.98M
4
KRYS icon
Krystal Biotech
KRYS
+$7.02M
5
ACLX
Arcellx
ACLX
+$5.99M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$12.3M
2
BIIB icon
Biogen
BIIB
+$11.4M
3
VTYX
Ventyx Biosciences
VTYX
+$3.3M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$2.97M
5
KYNB
Kyntra Bio
KYNB
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 81.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDX icon
76
Aldeyra Therapeutics
ALDX
$104M
$296K 0.08%
44,348
-105,652
-70% -$784K
NAMSW icon
77
NewAmsterdam Pharma Warrant
NAMSW
$84.9M
$260K 0.07%
137,000
+100,000
+270% +$194K
NCEL
78
NewcelX Ltd
NCEL
$21.5M
$140K 0.04%
501
-499
-50% -$179K
ARAV
79
DELISTED
Aravive, Inc. Common Stock
ARAV
$45.7K 0.01%
+346,511
New +$218K
RCKTW icon
80
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$7.5K ﹤0.01%
75,000
– –
AXSM icon
81
Axsome Therapeutics
AXSM
$11.7B
– –
-12,500
Closed -$898K
BBIO icon
82
PUT
BridgeBio Pharma
BBIO
$16B
– –
-376,000
Closed -$6.47M
BIIB icon
83
Biogen
BIIB
$29.9B
– –
-40,000
Closed -$11.4M
CABA icon
84
Cabaletta Bio
CABA
$465M
– –
-125,000
Closed -$1.61M
KYNB
85
CALL
Kyntra Bio
KYNB
$29M
– –
-13,600
Closed -$918K
KYNB
86
Kyntra Bio
KYNB
$29M
– –
-39,332
Closed -$2.65M
KYNB
87
PUT
Kyntra Bio
KYNB
$29M
– –
-39,332
Closed -$2.65M
JSPR icon
88
Jasper Therapeutics
JSPR
$26.8M
– –
-47,695
Closed -$653K
MDGL icon
89
CALL
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-53,100
Closed -$12.3M
MLYS icon
90
Mineralys Therapeutics
MLYS
$2.38B
– –
-62,500
Closed -$1.07M
VIR icon
91
Vir Biotechnology
VIR
$1.55B
– –
-20,000
Closed -$491K
VRDN icon
92
CALL
Viridian Therapeutics
VRDN
$2.1B
– –
-130,400
Closed -$3.1M
VTYX
93
DELISTED
Ventyx Biosciences
VTYX
– –
-100,696
Closed -$3.3M
WHWK
94
Whitehawk Therapeutics
WHWK
$191M
– –
-187,675
Closed -$1.28M
VINC
95
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-74,639
Closed -$1.94M
ALPN
96
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-118,891
Closed -$1.22M
ARAV
97
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-33,600
Closed -$42.3K
ARAV
98
PUT
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-861,200
Closed -$1.09M
RETA
99
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-29,105
Closed -$2.97M
KDNY
100
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-321,017
Closed -$12.3M
1 2 3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Affinity Asset Advisors held 101 positions worth $356M, up 24% from $286M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $89M of net new capital in Q3 2023, opening 33 new positions and adding to 27 existing holdings. Its largest new stake was Apogee Therapeutics: 1,045,110 shares worth $22.3M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $2.42M trimmed.

  • Affinity Asset Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,045,110 shares worth $22.3M.
  • Affinity Asset Advisors added most to Xenon Pharmaceuticals in Q3 2023, an estimated $8.98M increase.
  • Affinity Asset Advisors's biggest Q3 2023 reduction was SpringWorks Therapeutics, cutting an estimated $2.42M.
  • Affinity Asset Advisors fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $12.3M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $356M portfolio in Q3 2023.
  • Affinity Asset Advisors opened 33 new positions and closed 20 in Q3 2023.
  • Affinity Asset Advisors's portfolio value rose 24% quarter-over-quarter to $356M.

Based on Affinity Asset Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.